NT 157

Drug Profile

NT 157

Alternative Names: NT157

Latest Information Update: 04 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer TyrNovo
  • Class Small molecules
  • Mechanism of Action Insulin receptor substrate protein inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Malignant melanoma; Ovarian cancer; Prostate cancer
  • Research Acute lymphoblastic leukaemia; Osteosarcoma

Most Recent Events

  • 03 Dec 2016 Early research in Acute lymphoblastic leukaemia in Israel (IV) before December 2016
  • 03 Dec 2016 Pharmacodynamics data from a preclinical trial in Acute lymphoblastic leukemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top